Westmount Partners LLC Trims Position in Astrana Health, Inc. (NASDAQ:ASTH)

Westmount Partners LLC lowered its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 90,334 shares of the company’s stock after selling 1,799 shares during the period. Astrana Health accounts for approximately 0.9% of Westmount Partners LLC’s holdings, making the stock its 25th biggest holding. Westmount Partners LLC owned 0.16% of Astrana Health worth $2,848,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ASTH. GAMMA Investing LLC purchased a new position in shares of Astrana Health during the third quarter valued at about $34,000. Nisa Investment Advisors LLC bought a new stake in shares of Astrana Health during the 3rd quarter valued at $35,000. KBC Group NV bought a new position in shares of Astrana Health in the 3rd quarter worth about $70,000. Quarry LP purchased a new position in Astrana Health during the 3rd quarter valued at about $77,000. Finally, Quest Partners LLC bought a new stake in Astrana Health during the third quarter worth about $133,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ASTH shares. Truist Financial dropped their price target on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday. KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, TD Cowen assumed coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $63.67.

Astrana Health Stock Up 2.4 %

Shares of ASTH traded up $0.71 during trading hours on Monday, hitting $30.19. The company had a trading volume of 165,445 shares, compared to its average volume of 325,579. The company’s fifty day moving average price is $39.55 and its two-hundred day moving average price is $47.05. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a one year low of $29.08 and a one year high of $63.20. The company has a market capitalization of $1.70 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 1.80 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter in the previous year, the firm posted $0.47 EPS. As a group, equities analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.